Dashboard
Amgen Inc.
AMGNNASDAQFor informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.
Universal block
Live market data + trailing fundamentals.
Recent events
Material filings, federal awards, and regulatory activity. Impact is scored against market cap.
- Nov 9Ownership changeSEC
SEC Form 4 insider transaction filing dated 2026-11-09.
- Nov 9Ownership changeSEC
SEC Form 4 insider transaction filing.
- Nov 9Ownership changeSEC
Form 4 filing reports change in Amgen insider beneficial ownership.
- Nov 9Ownership changeSEC
SEC Form 4 insider transaction filing.
- Nov 3Financial resultsSEC
Amgen files 8-K (items 2.02, 9.01) disclosing results of operations and financial condition.
- Oct 27LeadershipSEC
Amgen filed 8-K item 5.02 on director/officer departure, election or appointment.
- Aug 13Ownership changeSEC
Form 4 insider transaction filing.
- Aug 12Ownership changeSEC
SEC Form 4 insider transaction filing.
- Aug 10Ownership changeSEC
SEC Form 4 insider trading filing reported.
- Aug 10Ownership changeSEC
SEC Form 4 insider transaction filing.
- Aug 10Ownership changeSEC
SEC Form 4 insider transaction filing.
- Aug 7Ownership changeSEC
SEC Form 4 insider transaction filing for Amgen Inc.
- Aug 7Ownership changeSEC
SEC Form 4 insider transaction filing.
- Aug 4Financial resultsSEC
Amgen 8-K filed with items 2.02 and 9.01 on financial results.
- Aug 4RegulatoryFDA
FDA supplemental submission (SUPPL-210) for Neulasta (BLA125031) dated 2026-08-04.
- Jul 31OtherSEC
Amgen 8-K discloses material cybersecurity incident under Item 1.05.
- Jul 16RegulatoryFDA
FDA supplemental submission (SUPPL-5202) for NEUPOGEN (BLA103353) filed 2026-07-16.
- Jun 23RegulatoryFDA
FDA supplemental submission (SUPPL-224) for PROLIA (BLA125320) with status date 2026-06-23.
- Jun 23RegulatoryFDA
FDA supplemental submission (SUPPL-225) for PROLIA (BLA125320) filed 2026-06-23.
- Jun 3Trial initiationClinicalTrials.gov
Phase 1/2 TINI 2 trial (NCT05848687) for infant ALL recruiting
Not financial advice — research and opinion only. Disclosures